Alesi Surgical are pleased to be supporting the up and coming HCSA annual conference on the 27th & 28th November 2018

Alesi Surgical are pleased to again be supporting the up and coming HCSA annual conference on the 28th & 29th November 2018 at Cardiff City Hall and are proud to be providing Gold standard sponsorship. We recognise the focus and attention of procurement within the NHS on improving theatre efficiencies whilst improving patient outcomes. Alesi Surgical is at the forefront, working with trusts across the country, supporting the role that procurement plays as a key enabler in adopting new and innovative technologies such as Ultravision™.

Come and visit us on stand 22 to understand how Alesi Surgical Ltd can help drive efficiencies and add value, whilst improving patient outcomes and providing a safer working environment for NHS staff.

 

Alesi Surgical to exhibit at the 47th AAGL Global Congress – Las Vegas Nov 11th – 15th – Booth 731

Alesi Surgical will be exhibiting at the 47th Annual Global Congress on Minimally Invasive Gynaecologic Surgery, at Booth 731 , which is being held at the MGM Grand, Las Vegas from November 11-15, 2018.

Alesi will be joined at the Congress by Dr David Levine, a leading laparoscopic gynaecologist, who will be sharing his views on Ultravision and the benefits that it brings in surgery.

This Congress is organised by the American Association for Gynaecological Laparoscopy (“AAGL”), one of the largest medical specialty societies focused on gynaecologic surgery.  The AAGL includes over 7,500 physicians and health care providers that are committed to advancing minimally invasive gynecologic surgery (MIGS).  AAGL’s Annual Global Congress is the premiere scientific event in its field, providing the latest education and best practices in MIGS.

More information on the Congress can be found at https://2018.aagl.org/.

 

A1_Presentation_Board (002)

Alesi Surgical at ACS Boston -21st to 25th October

Alesi Surgical will be exhibiting at the American College of Surgeons (“ACS”) Congress which is being held at the Boston Convention and Exhibition Centre, Boston, from October 21-25, 2018.

The Clinical Congress is a scientific and educational meeting whose purpose is to keep ACS Members and interested non-Fellow physicians abreast of the current status of the art and science of surgery. The Congress offers a highly diversifiedprogram of continuing education in all specialties of surgery and in important fields of science, socioeconomics, and medical education. It holds the preeminent place among all College activities designed to raise the standards of surgical practice and improve the care of the surgical patient. Registration is open to all physicians and individuals in the health care field and more information can be found at https://www.facs.org/clincon2018.

Alesi will be located at Booth 684.

Alesi Surgical sponsoring LIGO Surgical Masters Course in San Francisco – April 12th – 14th – San Francisco

Alesi Surgical is delighted to be sponsoring the LIGO Surgical Masters’ Course in Total Laparoscopic Hysterectomy & Advanced Laparoscopic Procedures, which is being held at on April 12-14 2018, at The Palace Hotel, San Francisco.

With the goal of increasing the practice of minimally invasive techniques, Dr. Kate O’Hanlan founded the Laparoscopic Institute for Gynecology and Oncology® (LIGO) in 2006. Devoted to training gynecologic general and oncologic surgeons in minimally invasive laparoscopic procedures, LIGO is the only training institute of its kind. Through an intensive hands-on course, LIGO has trained over 2,100 gynecologic surgeons from around the world.

The LIGO course is widely recognised as the leading course of its kind in the United States. It is implemented in accordance with the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American College of Obstetricians and Gynecologists and LIGO.  The American College of Obstetricians and Gynecologists is accredited by the ACCME to provide continuing medical education for physicians.

Charlie Le Doux, Vice President of Sales and Marketing at Alesi Surgical Technologies Inc, commented “Gynaecologists in the United States are rapidly realising the benefits that Ultravision brings to both them and their patients through a combination of enhanced visualisation, surgical smoke elimination and carbon dioxide minimisation.  I have worked with Dr O’Hanlan and her team for over 10 years to help bring advanced technologies to gynaecologists in the United States and beyond.  The LIGO course is a wonderful opportunity to showcase the Ultravision technology to over 150 attendees through practical demonstration and real-world use.”

For further information on the LIGO please visit https://ligocourses.com/

LIGO

 

Alesi Surgical are pleased to be supporting the up and coming HCSA on the 29th & 30th November 2017

Alesi Surgical are pleased to be supporting the up and coming HCSA on the 29th & 30th November 2017 in Harrogate International Centre, providing Gold standard sponsorship. We are keen to support, demonstrate and deliver on the expectations regarding developments around life sciences innovation & efficiency across the NHS. Supporting the role that procurement plays as a key enabler to the rapid adoption and diffusion of new and innovative technologies such as Ultravision. Delivering long term focus on added value which will lead for better patient outcomes, more efficient laparoscopic procedures and a safer environment within the operating room workplace.

Come and visit us on stand 12 and enjoy a workshop with Gary Welch (Director of Procurement and Supply Chain, Oxford University Hospitals NHS Foundation Trust.Programme Director, Shelford Group Procurement Programme) on “Efficiency & Innovation. How procurement can drive efficiencies and productivity in the NHS. (A case study in Laparoscopic Surgery at Oxford.)” @GaryWelch1

https://nhsprocurement.org.uk/event/2017-hcsa-annual-conference-and-exhibition/

 

HCSA1

Alesi Surgical to exhibit at the American Association of Gynaecological Laparoscopy in Washington DC – November 12th -16th, 2017.

Alesi Surgical is delighted to be exhibiting at the 46th American Association of Gynaecological Laparoscopy Global Congress on Minimally Invasive Gynaecology Surgery.  The meeting is being held at the Gaylord National Resort and Convention Center, National Harbor, Greater Washington, D.C. from November 12-16, 2017.  This is the first time that the Ultravision technology, the Company’s unique surgical smoke management technology, has been presented to gynaecologists in the United States.

 

Charlie Le Doux, Vice President of Sales and Marketing at Alesi Surgical Technologies Inc, commented “The theme of this year’s Congress is Enhancing Minimally Invasive Gynecologic Surgery Through Quality, Patient Safety and InnovationAlesi Surgical’s pioneering Ultravision technology is absolutely consistent with this theme.  Through enhanced visualisation, surgical smoke management and the minimisation of carbon dioxide exposure for patients Ultravision provides a unique combination of benefits for gynaecologists in the United States and beyond”.

 

Alesi Surgical will be on booth 13. More information on the AAGL and the Congress can be found at https://www.aagl.org/globalcongress/.

Alesi Surgical to exhibit at the American College of Surgeons Congress in San Diego.

Alesi Surgical is delighted to be exhibiting at The American College of Surgeons (ACS) Clinical Congress, one of the largest international meetings of surgeons in the world, being held in San Diego October 22-26 2017.

 

The Congress provides surgeons, medical students, surgical residents, and other members of the operating room team with the opportunity to immerse themselves in a variety of educational experiences and to interact with their peers.  The hallmarks of the Clinical Congress are a broad range of outstanding hands-on and didactic learning opportunities and timely discourse on the most relevant surgical practices and research, along with unparalleled access to peers.

 

The Congress is the first opportunity to showcase the Company’s Ultravision technology and its recently FDA cleared 5mm Trocar.  Charlie Le Doux, Vice President of Sales and Marketing at Alesi Surgical Technologies Inc, commented “The ACS is the premier general surgery meeting in the United States every year.  It will give US general surgeons and their colleagues exposure to Alesi Surgical’s Ultravision technology.  Ultravision’s unique mode of action provides them with the unrivalled combination of enhanced visualisation, surgical smoke management and carbon dioxide minimisation”.

 

Alesi Surgical’s booth number is 1350.  More information on the American College of Surgeons and its congresses can be found at https://www.facs.org/.

 

Alesi Surgical gains crucial FDA product clearance and targets US and Asia Pacific markets

Alesi Surgical Limited, the leading innovator of minimally invasive surgery technologies, has achieved a significant milestone, receiving United States FDA clearance for its world-first Ultravision Trocar device. This follows last year’s pivotal FDA clearance of the Ultravision technology.his development follows the announcement in June 2017 of the multi-million- pound funding from its existing investors Finance Wales and IP Group, and new investors Panakes Partners and EarlyBird Venture Capital.

Following this latest achievement, and as part of the ambitious global strategy Alesi has established a US subsidiary, Alesi Surgical Technologies Inc. It is also making key appointments of new personnel to spearhead growth in North America and the Asia Pacific Rim, whilst continuing its efforts to bring the Ultravision technology to operating theatres in the UK, Europe and Middle East.

The key appointments are Charles LeDoux, US Vice President of Commercial Development, and Michael Inouye, Country Manager for Japan and Asia Pacific.

Dr Dominic Griffiths, Managing Director of Alesi Surgical, said: “We are absolutely delighted that we have received FDA clearance for the Ultravision Trocar device. This technology will make a real difference for surgeons, operating theatre staff and patients in the laparoscopic surgical field across the world.

“With FDA and other regulatory approvals in hand, it is time for Alesi to accelerate its growth. Charles LeDoux and Michael Inouye will lead the commercial activities and provide the vital inroads that will enable key clinical staff and patients to benefit from the Ultravision technology in the USA and Japan, as is already the case in Europe and the Middle East.”

The UltravisionTM system is the world’s first use of electrostatic technology to clear the vapour and particulate matter – so called “surgical smoke” – that is generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.

By integrating its technology with a trocar, the company has expanded its range of Ultravision consumables. Trocars are the devices used to access the abdominal cavity and typically 3-5 trocars are used in each of the millions of laparoscopic procedures performed worldwide each year.

Charles LeDoux, who has developed multi-million-dollar sales operations within the US medical device sector, whilst Vice President of Sales for Conmed Corporation, said: “Having worked for some of the world’s finest and best known medical device and healthcare companies, I’ve been looking for a product that improves the outcome of a patient’s surgery, enhances the surgeons’ technique and finally satisfies the economic challenges faced by the industry. The Ultravision technology is the first product I’ve come across that genuinely meets all these three criteria without question.”

Michael Inouye, who has many years’ experience of setting up and implementing multi-million-pound medical device distribution networks in Japan and across Asia, said: “I am really excited at the prospect of delivering the pioneering Ultravision technology to this part of the world. The Japanese laparoscopic (minimally invasive surgery) sector is one of the most mature markets of its type anywhere, second only to the United States in scale.

“Japan therefore is a key area of focus but we will also be looking to target South Korea and Taiwan as they too have been practicing laparoscopic techniques for many years and have sizable domestic markets as a result.”

The revolutionary Ultravision technology produces a low-energy electrostatic charge and can greatly improve visibility for surgeons by actively eliminating surgical smoke as it is created by the cutting instrument. Improving surgeons’ visibility improves the safety of the procedure, whilst minimising healthcare professionals’ exposure to surgical smoke is increasingly important worldwide because of concerns over the health risks of long-term exposure.

The technology also benefits the patient because it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – that a patient is exposed to during the keyhole procedure.  Excessive use of carbon dioxide contributes to cardiovascular problems, complications in anesthesia, post-surgical pain and longer recovery time for the patient.

Surgeons across the UK have confirmed the Ultravision technology as facilitating the advancement of keyhole surgery and helping to improve patient outcomes.

For more information, contact James Barton at 2B Communications Limited on 07955 227046 or james@2bcommunications.co.uk

Notes to editors

  1. Alesi Surgical founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), has developed and commercialised Ultrasounds, the world’s first system that eliminates laparoscopic surgical smoke without the need for gas exchange.

Alesi Surgical raises €6m (£5.2m) to accelerate commercialisation of breakthrough product Ultravision

 

Alesi Surgical Limited, the leading innovator of minimally invasive surgery technologies – including the world-first Ultravision device – has successfully raised a further €6m (£5.2m) funding from both new and existing investors.

The new investment comes from two leading med tech European venture capital firms, Panakes Partners and Earlybird, with continued support from Alesi Surgical’s existing shareholders, IP Group plc and Finance Wales Limited.

The funds raised will be used to drive commercial expansion of both Alesi Surgical and Ultravision into the United States and other key markets worldwide, and to undertake additional research and development around the new Ultravision technology.

Alesi Surgical also announces the appointment of three new directors, strengthening its board with key expertise to take the company and its products forward. Joining as non-executive director Phil Cooper previously President at Molnlycke Healthcare, is a recognised leader in global commercialisation and growth of privately owned companies in the med tech sector.

As part of the investment Mr Thom Rasche, Partner at Earlybird and previously Vice President Europe of Ethicon Endosurgery; and Mr Alessio Beverina, Founding Partner at Panakes Partners, will both join the board as investor directors.

Dr Dominic Griffiths, Managing Director of Alesi Surgical said: “Earlybird and Panakes are two highly respected European venture capital companies and in such a competitive funding environment their interest in Alesi and UltravisionTM speaks volumes for our potential. With the three new additions to the board we have expanded our expertise in this market and having four corporate investors places us in a strong position for future growth.”

The funds have been raised following the recent approval of the company’s leading proprietary technology platform, UltravisionTM, by both the US FDA (Food and Drug Administration) and Japanese Ministry of Health, and the commercial traction it is already gaining in already approved markets in Europe and the Middle East.

The UltravisionTM system is the world’s first use of electrostatic technology to clear the vapour and particulate matter – so called “surgical smoke” – that is generated by modern surgical cutting instruments during abdominal keyhole (laparoscopic) surgery.

The revolutionary medical device produces a low-energy electrostatic charge and can greatly improve visibility for surgeons by actively eliminating surgical smoke as it is created by the cutting instrument. Minimising healthcare professionals’ exposure to surgical smoke is increasingly important worldwide because of concerns over the health risks of long-term exposure.

The technology also benefits the patient as it minimises the amount of cold, dry carbon dioxide gas – used to create a working space inside the abdomen – that a patient is exposed to during the keyhole procedure. Excessive use of carbon dioxide contributes to cardiovascular problems, complications in anesthesia, post-surgical pain and longer recovery time for the patient.

Thom Rasche, Partner of Earlybird, said: “Obscuring of the surgical view during the laparoscopic procedure is not only cumbersome to surgeons but adds an additional risk to the safety of the procedure and to the staff being exposed to the smoke. Alesi has developed a fabulous, simple and very effective solution to help address these risks.”

Alessio Beverina said: “I am delighted to support the Alesi development. Its unique patented technology is a smart and simple solution for a real problem for laparoscopic surgeons and nurses in the operating room, both in standard and robotic operations. Whilst Alesi’s Research and Development product pipeline promises to be a game changer in the sector.”

Notes to editors:

For more information, contact James Barton at 2B Communications on 07955 227046 or james@2bcommunications.co.uk

  1. Alesi Surgical develops and commercialises products that improve the safety, efficiency and outcomes of advanced surgical procedures.
  1. The company was founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), with the vision of becoming a world leader in surgical devices. Part of Cardiff University, WIMAT runs multi-disciplinary training courses across a range of surgical and medical specialties and is the busiest multi-disciplinary training centre in the United Kingdom.
  1. For more information, visit alesi-surgical.com
  1. Alesi Surgical is based at Cardiff Medicentre,the dedicated medical, healthcare, and life sciences business incubator located on the University Hospital of Wales campus. The latter is also home to Cardiff University’s School of Medicine.  Cardiff University is Wales’s leading Higher Education Institution for innovation, ranked 7th in the UK and 45th in Europe for innovation by Thomson Reuters.
  1. Finance Wales was established by the Welsh Government in 2001 and provides commercial funding to small and medium-sized businesses throughout Wales to enable them to realise their potential for innovation and growth. The company is part of the Finance Wales Group and in 2015-16 the Group invested £63 million through 268 debt-equity investments in growing businesses. The Finance Wales Group, one of the UK’s largest SME investors, has in excess of £990 million of funds under management across all SME investment fund and the Help to Buy – Wales scheme. The Group has invested more than £484 million through more than 4,018 investments.
  1. IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiary IP Capital), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 100 early-stage to mature businesses across four main sectors — Biotech, Cleantech, Healthcare and Technology. The Company is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.
  1. About Panakes Partners

Panakès Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel, improving both patient outcomes and healthcare economics. Investments focus on the medical device, diagnostics and healthcare IT fields. Panakès Partners is headquartered in Milan, Italy. www.panakes.it.

  1. About Earlybird

Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. With over EUR 850 million under management, six IPOs and 22 trade sales, Earlybird is one of the most successful venture capital firms in Europe.

For further information: www.earlybird.com, Twitter: http://www.twitter.com/EarlybirdVC.LinkedIn: www.linkedin.com/company/earlybird-venture-capital or Facebook: www.facebook.com/EarlybirdVC

 

Alesi Surgical attending “British Society of Gynaecological Endoscopy Annual Scientific Meeting 2017” 18th – 19th May, Hull

Alesi Surgical, manufacturer of the revolutionary Ultravision laparoscopic visual field clearing system, is delighted to be supporting this year’s BSGE AGM Meeting being held at Hull City Hall.

The theme of this year’s meeting is ‘Where are we now and where are we going……’

We are looking forward to discussing with existing and future users of Ultravision how it is providing benefits to patients, operating theatre personnel and hospitals when used in Gynaecology and other laparoscopic procedures.  Ultravision is the only technology that manages surgical smoke and plume without gas filtration or exchange, thereby maximising surgical efficiency whilst minimising patient exposure to carbon dioxide.

The full agenda can be found here:

http://www.bsge2017.org/programme/

 

BSGE LogoASM 17